NS101 (sudden sensorineural hearing loss)
Phase 2A Korean Phase 1b/2a trial in sudden sensorineural hearing loss at 15 hospitals with 113 participants enrolled, now listed as completed on ClinicalTrials.gov.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has completed a Korean Phase 1b/2a hearing-loss trial of its FAM19A5 antibody and continues dementia research alongside it.
Roles often seen at this stageClinical & PV · Research & development · Data & AI
Develops NS101, an antibody against the synapse-loss protein FAM19A5, for hearing loss, dementia and other neurological diseases.
A Korean Phase 1b/2a trial in sudden sensorineural hearing loss at 15 hospitals with 113 participants enrolled, now listed as completed on ClinicalTrials.gov.
An investigator-initiated trial in frontotemporal dementia, approved by Korea's Ministry of Food and Drug Safety in 2025.
Published results showing reversal of synapse loss and cognitive decline in Alzheimer's mouse models, and confirmed safety in a Phase 1a study of healthy adults in Canada.
Published a paper in Alzheimer's Research & Therapy showing that FAM19A5 inhibition reverses synapse loss and cognitive decline in Alzheimer's mouse models.
The NS101 Phase 1b/2a trial in sudden hearing loss was updated to completed on ClinicalTrials.gov.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.